Precision BioSciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DTIL | PRQR | PRME | EDIT | NTLA | SCTX | |
|---|---|---|---|---|---|---|
| Market cap | 226.84M | 198.98M | 901.44M | 417.74M | 1.72B | 317.67M |
| P/E (TTM) | 32.5 | — | — | — | — | — |
| Forward P/E | -4.4 | -3.0 | -5.6 | -3.6 | -4.8 | -4.6 |
| Price/book | 4.4 | 2.2 | 22.1 | 4.0 | 2.4 | -0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +5.29% | −42.44% | +3.41% | −6.47% | −12.60% | −14.60% |
| Today | +16.50% | +2.92% | +9.23% | +4.62% | +3.79% | +3.58% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All DTIL news ›Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 - - Dosed first patient with PBGENE-DMD at Arkansas Children's Hospital in…
More from 1 other outlet
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Details of the oral presentation: Further details on the trial can be found on Precision’s website and on clinicaltrials.gov under identifier NCT06680232. Since cccDNA is the only source of infectious particles (HBV DNA), we believe…
Precision BioSciences Reports Q3 2026 Results, $108 Million Cash Balance
TradingView Precision BioSciences Reports Q3 2026 Results, $108 Million Cash Balance Precision BioSciences reported a third-quarter 2026 net loss of $7.6 million, compared with a $21.8 million loss a year earlier, and ended Se
Precision BioSciences (DTIL) Set to Release Earnings on Monday
DTIL stock opened at $6.64 on Monday. Precision BioSciences has a 1-year low of $3.53 and a 1-year high of $9.62. The firm has a market cap of $183.26 million, a P/E ratio of -2.37 and a beta of 1.27. The business’s 50 day moving average…
Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Price Target of $32.25
Posted by Mitch Edgeman on Oct 17th, 2026 Check Out Our Latest Report on Precision BioSciences Precision BioSciences stock opened at $5.77 on Monday. The stock’s 50 day moving average price is $7.09 and its 200 day moving average price is…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biospace.com1
- defenseworld.net1
- stocktitan.net1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.